Most of the confusion after the July votes traces back to one thing: the market treats three separate legal events as a single event. Here is the actual machinery, in the order it runs, with the part everyone skips.
The three events people collapse into one
| Event | What it is | What it changes |
|---|---|---|
| Removal from Category 2 | FDA drops the “significant safety concern” designation pending review | Clears a blocker. Grants nothing. |
| PCAC recommendation | A non-binding advisory committee vote | Signals. Legally, nothing. |
| Bulks list placement | Completed notice-and-comment rulemaking | This is the one that grants compounding authority |
Six peptides completed step two on July 23–24, 2026. Zero have completed step three. When you see a vendor or clinic implying that a compound is “now legal,” that is the gap they are walking through.
What a 503A pharmacy actually is
Section 503A of the Federal Food, Drug, and Cosmetic Act carves out traditional pharmacy compounding: a licensed pharmacist preparing a customized medication for an identified individual patient against a valid prescription. Not a batch. Not inventory. One patient, one order.
Because those preparations are not FDA-approved drugs and do not go through premarket review, the statute constrains what raw material a 503A pharmacy may start from. Bulk substances must either be components of an approved drug, appear in an applicable USP or NF monograph, or be on the FDA’s 503A bulks list. That third door is what the PCAC votes were about.
503A: patient-specific compounding against an individual prescription, state-board regulated, no batch manufacturing.
503B: outsourcing facilities producing batches without patient-specific prescriptions, registered with the FDA and held to current good manufacturing practice standards.
The four-factor test
When the FDA evaluates a nominated bulk substance, staff apply four criteria:
- Chemical characterization — can the substance be defined, identified, and reproduced consistently?
- Safety — what does the human safety record look like?
- Evidence of effectiveness — is there support for the proposed use?
- Historical use in compounding — has it been compounded before, and with what outcomes?
In July, FDA reviewers applied this framework to all seven nominated peptides and recommended against every one. The committee then voted the other way on six. That divergence is the whole story of the meeting, and factor one — chemical characterization — was the recurring sticking point.
Why factor one should matter to you regardless
Set the regulatory fight aside for a second. The FDA’s objection was that without an accepted chemical definition, you cannot verify that two vials labeled with the same name contain the same thing at the same purity.
That is not a hypothetical problem in the compounding channel. It is the everyday condition of the research-grade channel. The entire reason lot-specific third-party testing matters is that the label alone is not load-bearing. The agency just spent two days articulating, in regulatory language, the exact reason experienced buyers insist on a COA.
What a completed listing would actually get you
If the FDA runs rulemaking and finalizes placement for, say, BPC-157, the resulting access looks like this: you see a licensed clinician, they determine a legitimate medical need, they write a prescription, a 503A pharmacy prepares it, you pay out of pocket because insurance will almost certainly not cover a compounded unapproved preparation.
That is a real improvement in oversight and a real increase in cost. It is not a retail shelf.
Public estimates for the full rulemaking runway on a favorable vote cluster between 8 and 24 months, and the FDA is not required to open rulemaking at all. Any content telling you a compound will be available on a specific date is guessing.
Where that leaves the two channels
The research channel and the prescription channel are not converging yet. They serve different buyers with different risk tolerances and different price points. What the July votes did was make the prescription channel plausible on a two-year horizon for compounds that had no pathway at all.
Research-use suppliers
Frequently Asked
It is the roster of bulk drug substances that a licensed 503A compounding pharmacy is permitted to use when preparing a preparation for an individual patient against a valid prescription. If a substance is not on it and is not an approved drug ingredient, a 503A pharmacy generally cannot compound with it.
503A pharmacies compound patient-specific preparations against individual prescriptions. 503B outsourcing facilities produce larger batches without patient-specific prescriptions and are held to stricter manufacturing standards. They operate under different rules and different bulk substance lists.
Category 2 is the FDA’s designation for nominated substances that raise significant safety concerns pending review. Removal from Category 2 is a separate event from PCAC recommendation, which is in turn separate from actual placement on the bulks list.
Estimates from law firms tracking the process range from roughly 8 months to 24 months, depending on how quickly the FDA opens a proposed rule and how contentious the comment period is. There is no statutory deadline forcing the agency to act at all.
No. Approval is the outcome of a completed new-drug application in which a sponsor submits safety and effectiveness data. Bulks list placement is a compounding-eligibility determination. They are different processes with different standards.